Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
22,954.00
(
0.01%
)
Dow Jones
45,960.11
(
-1.01%
)
Brent Oil
103.94
(
3.25%
)
Bitcoin
67,955.01
(
-1.21%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mouton29 post# 171816

Monday, 12/23/2013 4:06:57 PM

Monday, December 23, 2013 4:06:57 PM

Post# of 257295

If the CVR does not trade and does not have an ascertainable value, there is an argument that you can defer recognition. The Sanofi-Aventis disclosure [in the Genzyme deal] took the position that the receipt of the CVR was taxable, but that the subsequent tax consequences are unclear.

Thanks. I figured this would be a gray area, LOL.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today